Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $4 from $10 and keeps a Buy rating on the shares. The company’s Q4 results saw operating expenses slightly below estimate but a wider GAAP loss per share, the analyst tells investors in a research note. Maxim adds that its price target cut reflects share dilution for Dermata.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRMA: